European Human Genetics Conference 2007 June 16 – 19, 2007 ...
European Human Genetics Conference 2007 June 16 – 19, 2007 ...
European Human Genetics Conference 2007 June 16 – 19, 2007 ...
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Clinical genetics<br />
P0054. Population investigation of alpha-1-antitypsin in some<br />
regions of the Azerbaijan Republic<br />
A. B. Ismayilova;<br />
Baku State University, Baku, Azerbaijan.<br />
Alpha-1-antitrypsin (α1A) is low molecular protease inhibitor, synthesized<br />
by liver cells, which destroys neutrophil elastase of lung alveolar<br />
cells. So far, 90 mutant and normal alleles of the α1A gene are<br />
known.<br />
In our researches we have identified α1A phenotypes in healthy persons<br />
as well as in patients with lung and liver disease. Capillary blood<br />
(0,2 ml) with anticoagulation agent-heparin was collected in eppendorf<br />
tubes. Two regions of Azerbaijan Republic (Siyazan and Kazakh)<br />
were involved in population studies. Siyazan area is located 110 km<br />
northward and Qazakh area 450 km west-northward from Baku city.<br />
Altogether 897 person’s blood samples were screened.<br />
Phenotype testing was carried out by isoelectric focusing (IEF) in thin<br />
layer polyacrylamide- ampholine gels (PAAG), pH 4-6.<br />
Three normal phenotypes of PiM alleles were identified in homozygous<br />
as well as in compound state with frequencies of: M1M2- 32%,<br />
M1M3-20% and M2M3-12%. The frequency of PiM alleles was : M1-<br />
38%,M2-38% and M3-24%.<br />
In six families two types of mutations were defined as with PiZ (6 persons)<br />
and PiS (4 persons).<br />
IEF method in PAG with pH 4-6 is recommended for identifying phenotypes<br />
of alpha-1-antitrypsin in population studies.<br />
P0055. Microstomia- cleft palate: a new syndrome?<br />
S. A. Boyadjiev 1 , R. Saadeh 2 , A. Scott 2 , W. Tian 3 , A. Mian 3 , E. Wulfsberg 3 , T.<br />
Beaty 4 , C. Vander Kolk 5 , R. Redett 5 ;<br />
1 Section of <strong>Genetics</strong>, Sacramento, CA, United States, 2 McKusick-Nathans Institute<br />
of Genetic Medicine, The Johns Hopkins University School of Medicine,<br />
Baltimore, MD, United States, 3 Department of Pediatrics, University of Maryland,<br />
Baltimore, MD, United States, 4 Department of Epidemiology, The Johns<br />
Hopkins University School of Public Health, Baltimore, MD, United States, 5 Department<br />
of Surgery, Division of Plastic Surgery, The Johns Hopkins University<br />
School of Medicine, Baltimore, MD, United States.<br />
The unusual combination of extremely small mouth with U-cleft palate<br />
was observed in two unrelated families. While mild micrognatia was<br />
described in infancy, it was not obvious in later life. In fact, prominent<br />
and pointed chin was present in the affected adults. In the first family,<br />
a mother and her daughter had these oral anomalies and downslanting<br />
palpebral fisssures. No associated birth defects or delays were<br />
present. In the second family, the affected mother had a son and fraternal<br />
twin daughters with the same combination of oral features and<br />
brachydactyly and 5 th finger clinodactyly. In addition to the oral defects,<br />
the youngest boy in this family had craniosynostosis and ureteral obstruction<br />
resulting in chronic renal failure. Whole-genome genotyping<br />
with Illumina 317K SNP Beadchip did not detect chromosomal rearrangements.<br />
The diagnosis of Pierre Robin sequence was considered<br />
unlikely based on the clinical presentation and extracranial dysmorphisms.<br />
More than 50 syndromes featuring microstomia and cleft<br />
palate were reviewed and excluded. We propose that this condition<br />
represents a new autosomal dominant dysmorphic syndrome. Linkage<br />
analysis of these and additional families with similar features is likely<br />
to pinpoint the location of a gene essential for proper development of<br />
the oral region.<br />
P0056. Novel missense mutation: R131C in the RUNX2 gene in a<br />
case with cleidocranial dysplasia<br />
V. Belengeanu 1 , D. Steinberger 2 , S. Farcaş 1 , C. Popa 1 , K. Rozsnyai 1 , D. C.<br />
Bratu 3 ;<br />
1 Department of Medical <strong>Genetics</strong>, University of Medicine and Pharmacy,<br />
Timişoara, Romania, 2 Bioscientia Center for <strong>Human</strong> <strong>Genetics</strong>, Ingelheim,<br />
Germany, 3 Department of Orthodontics, University of Medicine and Pharmacy,<br />
Timişoara, Romania.<br />
Cleidocranial dysplasia is a skeletal dysplasia characterized by persistently<br />
open or delayed closure of sutures, hypoplastic and/or aplastic<br />
clavicles, wide pubic symphysis, dental anomalies, and short stature.<br />
The disorder is caused by heterozygous mutations in the CBFA<br />
(core binding factor alpha1) gene, also known as RUNX2 (runt-related<br />
gene 2) on chromosome 6p21, that encodes an osteoblast-specific<br />
transcription factor. Mutations scattered throughout the entire CBFA1<br />
gene have been related to this disorder, however, most of them affect<br />
the highly conserved Runt domain, abolishing the DNA-binding ability<br />
of the transcription factor. We report a case presenting with the classic<br />
phenotype of cleidocranial dysplasia, in which mutation analysis of<br />
the RUNX2 gene revealed a previously unreported missense mutation<br />
(391C>T), that replaces an arginine residue with a cysteine at position<br />
131, in the Runt homology domain of the RUNX2 protein. The mutation<br />
occurred the novo, neither of the parents, who were phenotypically<br />
normal, carried the mutation identified in the patient. We describe our<br />
detailed investigation of the patient, expanding the data related to the<br />
phenotypic expression of different mutations in the RUNX2 gene.<br />
P0057. Further Expansion of the Behavioral and<br />
Neurodevelopmental Phenotypic Prensentation of Boys with 49<br />
XXXXY ( A variant of XXY)<br />
C. A. Samango-Sprouse 1 , A. Gropman 1 , S. A. Rosenson 2 , A. Rogol 3 ;<br />
1 George Washington University, Washington, DC, United States, 2 University<br />
of Texas, Austin, TX, United States, 3 University of Virginia, Charlottsville, VA,<br />
United States.<br />
This is a comprehensive study completed on a large cohort of boys<br />
with 49 XXXXY (49XY) describing intact nonverbal IQ and receptive<br />
comprehension skills with severe developmental dyspraxia. 15 boys<br />
were evaluated using standardized measures by a multi-disciplinary<br />
team including pediatric neurology, genetics, endocrinolgy, development,<br />
physical therapy and speech/language.<br />
The mean age of the cohort was 37 months with mean birth weight of<br />
5lbs. 7ozs. The average age at the time of diagnosis was 4 mos. Mean<br />
Nonverbal IQ was 92 with receptive comprehension standard scores<br />
of 81.7 in contrast to depressed verbal capacities with standard scores<br />
of 66.5. There was severe motor praxis deficits with global hypotonia in<br />
all children. Sensory integration dysfunction was evident.<br />
These findings describe for the first time intact nonverbal skills and<br />
comprehension with severe motor planning deficits in boys with this<br />
rare disorder. This study expands the phenotypic presentation of 49<br />
XY to include better nonverbal IQ capacities than appreciated previously.<br />
Speech is severely delayed secondary to verbal and oral motor<br />
dyspraxia. The presence of limb dyspraxia affects graphomotor<br />
function. Behavioral issues were evident in some but not all children.<br />
These finding support evidence of frontal lobe dysfunction as previously<br />
demonstrated in boys with XXY.<br />
Counseling for newly diagnosed families needs to highlight variability<br />
of intellectual capabilities, the need for aggressive EI services with direct<br />
SPL and OT for motor planning deficits. Further studies are underway<br />
to further investigate phenotypic variability, MRI abnormalities and<br />
the presence of mosiacism in the higher functioning children.<br />
P0058. Cockayne Syndrome Type II: a unique phenotype<br />
among Druze Population in Northern Israel Caused by a Highly<br />
Prevalent Novel Mutation in the CSB Gene.<br />
T. C. Falik-Zaccai1,2 , M. Laskar1 , N. Kfir1 , W. Nasser3 , H. Slor4 , M. Khayt1 ;<br />
1 2 Istitute of Medical genetics, Western Galilee Hospital, Naharia, Israel, Rappaport<br />
Faculty of Medicine, Technion- Israel Institue of Technology, Haifa, Israel,<br />
3Department of Pediatric Nephrology, Western Galilee Hospital, Naharia, Israel,<br />
4Department of <strong>Human</strong> Molecular <strong>Genetics</strong> and Biochemistry, Sackler School of<br />
Medicine, Tel-Aviv University, Tel-Aviv, Israel.<br />
Cockayne Syndrome (CS) (OMIM # 2<strong>16</strong>400) is a rare autosomal recessive<br />
disease characterized by severe growth and developmental<br />
retardation, progressive neurological dysfunction and symptoms of<br />
premature aging. The primary cause of the disease is a defect in the<br />
transcription-coupled DNA repair, specifically the Nucleotide Excision<br />
Repair (NER) pathway. To date, four genes along this pathway CS-<br />
A, CS-B, XP-D and XP-G have been reported to be involved in the<br />
pathogenesis of CS.<br />
We have identified a large, highly consanguineous, Druze kindred<br />
descended from a single ancestor, with six CS patients. All patients<br />
presented with congenital severe phenotype that includes severe failure<br />
to thrive, severe mental retardation, congenital cataracts, loss of<br />
adipose tissue, joint contractures, bird-like faces with small, deep-set<br />
eyes and prominent nasal bridge, and kyphosis. All patients exhibited<br />
neither language skills nor independent sitting or walking and died by<br />
the age of 5 years.<br />
Cellular studies in patients‘ fibroblasts showed significant defect in<br />
transcription-coupled DNA repair (TCR) and a marked correction of<br />
the abnormal cellular phenotype with a plasmid containing the cDNA